According to IR at IMNX, that's correct: Tues and Wed. They seemed pretty tight-lipped----although polite in their response to my questions, it was clear they didn't want to give out too much info.
BTW, they did tell me something about TRAIL, one of the most interesting products in the pipeline, which is being developed in collaboration with DNA. It turns out that they have extended preclinicals to investigate some other applications in animal models and to determine which of several candidate variant forms of TRAIL ligand they would actually begin human trials with. I did not get the impression that the preclinical work with mice did not seem to be working out; rather, the impression was that there are additional applications for TRAIL besides those currently being pursued, and they wanted to get a better handle on that before beginning clinicals. One of the things they are delving into is using TRAIL as an adjunct to other chemotherapeutic regimens. Preliminarily, they tell me that TRAIL seems to enable longer chemotherapeutic courses, thus enhancing the efficacy. This has not been published yet, and they are just now working on a manuscript, which will probably be submitted in a couple of months. This is potentially very important (if it works out in clinicals), in that a much larger market for TRAIL is possible. Granted, if TRAIL ever makes it to market, it is still several years away, but sometimes it pays to look ahead a bit. To me, it looks very promising so far.
Disclaimer: all this info comes directly from IR at IMNX.
Regards,
Walkingshadow |
